Navigation Links
Select Medical Holdings Corporation Commences Initial Public Offering of Common Stock
Date:9/9/2009

MECHANICSBURG, Pa., Sept. 9 /PRNewswire/ -- Select Medical Holdings Corporation ("Select"), the parent of Select Medical Corporation, today announced the launch of its initial public offering of 33,333,333 shares of Select common stock. The initial public offering price is expected to be between $11.00 and $13.00 per share. This is a primary offering of common shares by Select, and Goldman, Sachs & Co., Morgan Stanley & Co. Incorporated, Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities Inc. are serving as joint bookrunners for the offering. The underwriters have the option to purchase from Select up to an additional 5,000,000 shares of common stock, on the same terms and conditions, to cover over-allotments, if any. Select has applied to have its common stock approved for quotation on the New York Stock Exchange under the symbol "SEM."

Select intends to use the net proceeds from the offering to repay indebtedness and to make payments to executive officers under Select's Long Term Cash Incentive Plan. Any remaining net proceeds will be used for general corporate purposes.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering of the common stock will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to this offering may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 85 Broad St., New York, NY 10004 or by faxing (212) 902-9316 or calling toll-free 1-866-471-2526 or emailing at prospectus-ny@ny.email.gs.com; or Morgan Stanley & Co. Incorporated, Attention: Prospectus Department, 180 Varick Street, New York, New York 10014 (email address: prospectus@morganstanley.com); or BofA Merrill Lynch, 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department; or J.P. Morgan Securities Inc., Attention: Prospectus Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by calling (718) 242-8002.

About Select

Select Medical Corporation is a leading operator of specialty hospitals in the United States. Select operates 87 long term acute care hospitals and five acute medical rehabilitation hospitals in 25 states, and 948 outpatient rehabilitation clinics in 37 states and the District of Columbia. Select also provides medical rehabilitation services on a contracted basis to nursing homes, hospitals, assisted living and senior care centers, schools and work sites. Select began operations in 1997 under the leadership of its current management team.


'/>"/>
SOURCE Select Medical Holdings Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Methodist Health System Selects Webmedx for Medical Transcription Technology and Services
2. Selective Insurance Group Announces Officer Appointments
3. Kroger Selects WaveSense Diabetes Testing Products
4. eDiets.com Selects Karlin+Pimsler to Lead Creative Turnaround
5. VNA of Hanover & Spring Grove Selects Cardiocom Telehealth Technology as Its New Telehealth Provider
6. Award-Winning Actress and Director Anjelica Huston Selected as Honorary Chair for L.A. Jewish Homes Walk of Ages X
7. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
8. Sandata Selected by Volunteer State Health Plan to Manage TennCare Choices
9. Stemedica Selected by World Stem Cell Summit to Present Scientific Discoveries
10. Greenberg Traurig Attorney Selected For Massachusetts Life Sciences Collaborative Task Force
11. Bioelements Selects Room 214 as Their Social Media and Online Marketing Agency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Journal of ... It can have severe consequences to overall dental health, including complications with speech, eating, ... turn to dental implants to replace lost teeth. As the number of tooth replacements ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Excellence upon National Registry of Emergency Medical Technicians and welcomes this ... said Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: